Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEZS-108 in Triple Negative Breast Cancer
NCT01698281Phase 2Terminated
- Sponsor
- COSCIENS Biopharma Inc.
- Start
- Dec 2012
- Primary completion
- Aug 2014
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 2
01
Overview
A Phase 2 trial of zoptarelin doxorubicin in breast cancer, sponsored by COSCIENS Biopharma Inc.. Started Dec 2012; status: terminated.
02
Drugs
zoptarelin doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01698281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01698281.